semaglutide and blindness Ozempic Lawsuit [2026 Update] TGA issues warning over GLP-1-based

Compounding pharmacies must stop making compounded versions of semaglutide in the next 60 to 90 days, depending on the type of facility, the agency said

Mancinelli C, Marx DC, Gonzalez-Hernandez AJ, et al

Essential amino acids and protein synthesis: insights into maximizing the muscle and whole-body response to feeding

The Dysesthesia Signal A unique safety signal associated with retatrutide is dysesthesiaan abnormal or unpleasant skin sensation such as tingling, burning, or increased sensitivity

Specifically, NRF2 is a transcription factor that governs the antioxidant pathway by targeting GSH metabolism-related genes